Selected References
Immunomodulators
Y. Azuma, K. Ohura (2004). Immunological modulation by lidocaine–epinephrine and
prilocaine–felypressin on the functions related to natural immunity in neutrophils and
macrophages.Curr. Drug Targ.: Immune, Endocr. Metabol. Disord. 4: 29–36.
S. Chada, R. Ramesh, A. M. Mhashilkar (2003). Cytokine- and chemokine-based gene therapy
for cancer. Curr. Op. Mol. Ther. 5: 463–474.
W. J. Fantl, S. Rosenberg (2000). Anti-angiogenesis as a therapeutic strategy for cancer. Ann.
Rep. Med. Chem. 35: 123.
M. Fischereder, M. Kretzler (2004). New immunosuppressive strategies in renal transplant recip-
ients.J. Nephrol. 17: 9–18.
I. Krause, G. Valesini, R. Scrivo, Y. Shoenfeld (2003). Autoimmune aspects of cytokine and
anticytokine therapies. Am. J. Med. 115: 390–397.
E. C. Lavelle, P. McGuirk, K. H. G. Mills (2004). Molecules of infectious agents as immunomod-
ulatory drugs. Curr. Top. Med. Chem. 4: 499–508.
S. H. Powis (1998). Lessons from an age-old war. Nature Medicine 4: 887–888.
M. J. Schultz, J. Kesecioglu, T. Van Der Poll (2004). Immunomodulating properties of
macrolides: animal and human studies. Curr. Med. Chem.: Anti-Inf. Ag. 3: 101–107.
J. S. Skotnicki, J. I. Levin (2003). TNF—a converting enzyme (TACE) as a therapeutic target.
Ann. Rep. Med. Chem. 38: 153.
B. K. Trivedi, J. E. Low, K. Carson, G. J. LaRosa (2000). Chemokines: Targets for novel thera-
peutics.Ann. Rep. Med. Chem. 35: 191.
A. O. Tzianabos (2000). Polysaccharide immunomodulators as therapeutic agents: structural
aspects and biologic function. Clin. Microbiol. Rev. 13: 523–533.
IMMUNOMODULATORS AND THEIR RECEPTORS 405